vs
ATLANTIC AMERICAN CORP（AAME）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
ATLANTIC AMERICAN CORP的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.5倍（$53.8M vs $35.5M），ATLANTIC AMERICAN CORP净利率更高（1.1% vs -304.2%，领先305.3%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 20.8%），ATLANTIC AMERICAN CORP自由现金流更多（$6.6M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 7.2%）
大西洋电报公司成立于1856年11月6日，主要业务是铺设并运营跨大西洋商业电报电缆，这也是人类历史上第一条跨大西洋的电信通信链路。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
AAME vs RXRX — 直观对比
营收规模更大
AAME
是对方的1.5倍
$35.5M
营收增速更快
RXRX
高出661.0%
20.8%
净利率更高
AAME
高出305.3%
-304.2%
自由现金流更多
AAME
多$53.9M
$-47.3M
两年增速更快
RXRX
近两年复合增速
7.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $53.8M | $35.5M |
| 净利润 | $577.0K | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 1.4% | -304.8% |
| 净利率 | 1.1% | -304.2% |
| 营收同比 | 20.8% | 681.7% |
| 净利润同比 | 128.9% | 39.6% |
| 每股收益（稀释后） | $0.02 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AAMERXRX
| Q4 25 | — | $35.5M | ||
| Q3 25 | $53.8M | $5.2M | ||
| Q2 25 | $55.3M | $19.2M | ||
| Q1 25 | $50.1M | $14.7M | ||
| Q4 24 | $49.0M | $4.5M | ||
| Q3 24 | $44.5M | $26.1M | ||
| Q2 24 | $47.7M | $14.4M | ||
| Q1 24 | $47.0M | $13.8M |
净利润AAMERXRX
| Q4 25 | — | $-108.1M | ||
| Q3 25 | $577.0K | $-162.3M | ||
| Q2 25 | $3.3M | $-171.9M | ||
| Q1 25 | $802.0K | $-202.5M | ||
| Q4 24 | $412.0K | $-178.9M | ||
| Q3 24 | $-2.0M | $-95.8M | ||
| Q2 24 | $-684.0K | $-97.5M | ||
| Q1 24 | $-2.0M | $-91.4M |
毛利率AAMERXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率AAMERXRX
| Q4 25 | — | -304.8% | ||
| Q3 25 | 1.4% | -3327.6% | ||
| Q2 25 | 7.6% | -916.8% | ||
| Q1 25 | 2.1% | -1297.9% | ||
| Q4 24 | 1.1% | -4042.4% | ||
| Q3 24 | -5.5% | -377.1% | ||
| Q2 24 | -1.8% | -697.4% | ||
| Q1 24 | -5.3% | -698.4% |
净利率AAMERXRX
| Q4 25 | — | -304.2% | ||
| Q3 25 | 1.1% | -3135.3% | ||
| Q2 25 | 6.0% | -894.2% | ||
| Q1 25 | 1.6% | -1373.3% | ||
| Q4 24 | 0.8% | -3935.5% | ||
| Q3 24 | -4.5% | -367.5% | ||
| Q2 24 | -1.4% | -676.6% | ||
| Q1 24 | -4.3% | -662.4% |
每股收益（稀释后）AAMERXRX
| Q4 25 | — | $-0.17 | ||
| Q3 25 | $0.02 | $-0.36 | ||
| Q2 25 | $0.15 | $-0.41 | ||
| Q1 25 | $0.03 | $-0.50 | ||
| Q4 24 | $0.01 | $-0.56 | ||
| Q3 24 | $-0.10 | $-0.34 | ||
| Q2 24 | $-0.04 | $-0.40 | ||
| Q1 24 | $-0.10 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $34.4M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $109.5M | $1.1B |
| 总资产 | $430.9M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资AAMERXRX
| Q4 25 | — | $743.3M | ||
| Q3 25 | $34.4M | $659.8M | ||
| Q2 25 | $46.4M | $525.1M | ||
| Q1 25 | $35.9M | $500.5M | ||
| Q4 24 | $35.6M | $594.4M | ||
| Q3 24 | $23.0M | $427.6M | ||
| Q2 24 | $21.2M | $474.3M | ||
| Q1 24 | $21.2M | $296.3M |
总债务AAMERXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益AAMERXRX
| Q4 25 | — | $1.1B | ||
| Q3 25 | $109.5M | $1.0B | ||
| Q2 25 | $106.2M | $919.1M | ||
| Q1 25 | $102.4M | $933.9M | ||
| Q4 24 | $99.6M | $1.0B | ||
| Q3 24 | $105.8M | $524.6M | ||
| Q2 24 | $100.7M | $584.4M | ||
| Q1 24 | $102.8M | $401.2M |
总资产AAMERXRX
| Q4 25 | — | $1.5B | ||
| Q3 25 | $430.9M | $1.4B | ||
| Q2 25 | $429.3M | $1.3B | ||
| Q1 25 | $388.4M | $1.3B | ||
| Q4 24 | $393.4M | $1.4B | ||
| Q3 24 | $387.0M | $726.5M | ||
| Q2 24 | $386.0M | $775.9M | ||
| Q1 24 | $365.8M | $557.8M |
负债/权益比AAMERXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $6.6M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $6.6M | $-47.3M |
| 自由现金流率自由现金流/营收 | 12.3% | -133.1% |
| 资本支出强度资本支出/营收 | 0.1% | 3.5% |
| 现金转化率经营现金流/净利润 | 11.51× | — |
| 过去12个月自由现金流最近4个季度 | $19.3M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流AAMERXRX
| Q4 25 | — | $-46.1M | ||
| Q3 25 | $6.6M | $-117.4M | ||
| Q2 25 | $9.3M | $-76.4M | ||
| Q1 25 | $-722.0K | $-132.0M | ||
| Q4 24 | $4.8M | $-115.4M | ||
| Q3 24 | $90.0K | $-59.2M | ||
| Q2 24 | $416.0K | $-82.2M | ||
| Q1 24 | $-5.3M | $-102.3M |
自由现金流AAMERXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | $6.6M | $-117.6M | ||
| Q2 25 | $9.1M | $-79.6M | ||
| Q1 25 | $-986.0K | $-133.8M | ||
| Q4 24 | $4.6M | $-116.7M | ||
| Q3 24 | $58.0K | $-63.8M | ||
| Q2 24 | $361.0K | $-83.4M | ||
| Q1 24 | $-5.4M | $-109.0M |
自由现金流率AAMERXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | 12.3% | -2272.5% | ||
| Q2 25 | 16.5% | -413.9% | ||
| Q1 25 | -2.0% | -907.4% | ||
| Q4 24 | 9.3% | -2567.7% | ||
| Q3 24 | 0.1% | -244.6% | ||
| Q2 24 | 0.8% | -578.5% | ||
| Q1 24 | -11.4% | -789.9% |
资本支出强度AAMERXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | 0.1% | 4.7% | ||
| Q2 25 | 0.3% | 16.4% | ||
| Q1 25 | 0.5% | 12.4% | ||
| Q4 24 | 0.5% | 28.6% | ||
| Q3 24 | 0.1% | 17.5% | ||
| Q2 24 | 0.1% | 8.2% | ||
| Q1 24 | 0.1% | 48.2% |
现金转化率AAMERXRX
| Q4 25 | — | — | ||
| Q3 25 | 11.51× | — | ||
| Q2 25 | 2.80× | — | ||
| Q1 25 | -0.90× | — | ||
| Q4 24 | 11.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AAME
| Bankers Fidelity | $30.0M | 56% |
| American Southern | $23.7M | 44% |
RXRX
暂无分部数据
